Nearly half a century since its introduction into clinical practice, mammography remains the criterion standard for breast cancer detection. Women who participate in a modern breast cancer screening program have 60% lower risk of dying from breast cancer within 10 years of diagnosis and 47% lower risk within 20 years compared with women who do not.1 Still, the mammogram is an imperfect screening tool, and the sensitivity for cancer detection is inversely proportional to breast density.2 False-positive rates in breast cancer screening are also a considerable limitation of mammography, and high callback rates may lead to unnecessary biopsies, increasing costs, and patient anxiety.3 Although cancer detection is most important, recall reduction is also a valuable metric for women undergoing screening mammography.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Tuite CM, DiNome ML, Goldstein LJ. Benefits of Digital Breast Tomosynthesis Beyond Baseline Screening. JAMA Netw Open. 2020;3(7):e2012361. doi:10.1001/jamanetworkopen.2020.12361
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: